Compare REPL & PAYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REPL | PAYS |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.6M | 485.8M |
| IPO Year | 2018 | 2020 |
| Metric | REPL | PAYS |
|---|---|---|
| Price | $12.21 | $12.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $5.67 | ★ $9.42 |
| AVG Volume (30 Days) | ★ 6.3M | 492.2K |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 85.71 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $24,120,434.00 |
| Revenue This Year | N/A | $33.83 |
| Revenue Next Year | N/A | $14.89 |
| P/E Ratio | ★ N/A | $106.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $3.08 |
| 52 Week High | $13.86 | $9.60 |
| Indicator | REPL | PAYS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The The company generates revenues from pharma card programs through card program management fees, transaction claim processing fees, interchange fees, customer service fees, other billable service fees and settlement income and other revenues are generated through cardholder fees, interchange fees, program management fees, load fees and breakage.